

1 STATE OF OKLAHOMA

2 1st Session of the 55th Legislature (2015)

3 HOUSE BILL 1628

By: Derby

4  
5  
6 AS INTRODUCED

7 An Act relating to the Oklahoma Health Care  
8 Authority; prohibiting SoonerCare program from  
9 routinely paying for quantitative drug screening;  
10 requiring SoonerCare program to pay for confirmatory  
11 quantitative drug testing if initial screen is  
12 positive under certain circumstances; permitting  
13 SoonerCare to pay for quantitative drug screening if  
14 certain knowledge will have impact on clinical  
15 decision-making; providing for noncodification; and  
16 providing an effective date.

17 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

18 SECTION 1. NEW LAW A new section of law not to be  
19 codified in the Oklahoma Statutes reads as follows:

20 A. The SoonerCare program shall not routinely pay for  
21 quantitative drug screening but shall pay for confirmatory  
22 quantitative drug testing if there is an initial qualitative urine  
23 drug test screen which is positive. Confirmatory quantitative urine  
24 drug testing is considered reasonable and necessary, following a  
25 qualitative screen, under the following circumstances:

1. Cocaine confirmation to identify a chronic cocaine user;

1           2. THC (tetrahydrocannabinoids) confirmation to document the  
2 patient's discontinuation of THC use according to the treatment  
3 plan;

4           3. Negative screen inconsistent with the patient's medical  
5 history or currently prescribed pain medications;

6           4. Suspicion of a specific drug use, such as but not limited to  
7 Fentanyl and Meperidine, or "designer drugs"; or

8           5. A confirmation drug screen is indicated when the result of  
9 the drug screen is different from that suggested by the patient's  
10 medical history, clinical presentation or a patient's own statement.

11           B. The SoonerCare program may also pay for quantitative drug  
12 screening if the knowledge of the absolute level of a drug will have  
13 an impact on clinical decision-making.

14           SECTION 2. This act shall become effective November 1, 2015.

15

16           55-1-5168           AM           01/12/15

17

18

19

20

21

22

23

24